Poseida Therapeutics Bilan de santé
Santé financière contrôle des critères 5/6
Poseida Therapeutics possède un total de capitaux propres de $87.2M et une dette totale de $58.9M, ce qui porte son ratio d'endettement à 67.5%. Son actif total et son passif total sont $293.6M et de $206.4M.
Informations clés
67.5%
Ratio d'endettement
US$58.91m
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$230.85m |
| Fonds propres | US$87.21m |
| Total du passif | US$206.37m |
| Total des actifs | US$293.58m |
Mises à jour récentes de la santé financière
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Recent updates
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%
Oct 19Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Sep 30Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Sep 09Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Aug 28Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?
Jan 25Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 09FDA lifts clinical hold on Poseida's prostate cancer cell therapy study
Nov 02Analyse de la situation financière
Passif à court terme: Les actifs à court terme de PSTX ( $250.7M ) dépassent ses passifs à court terme ( $78.3M ).
Passif à long terme: Les actifs à court terme de PSTX ( $250.7M ) dépassent ses passifs à long terme ( $128.1M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: PSTX dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de PSTX est passé de 52.1% à 67.5% au cours des 5 dernières années.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: PSTX dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: PSTX dispose d'une marge de trésorerie suffisante pour 1.7 ans si le flux de trésorerie disponible continue de croître à un taux historique de 10 % chaque année.